Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison

Autor: P. Nieto-Gómez, R. Ubago-Pérez, J. Cabeza-Barrera
Rok vydání: 2019
Předmět:
Zdroj: Actas Urológicas Españolas (English Edition). 43:355-363
ISSN: 2173-5786
DOI: 10.1016/j.acuroe.2019.03.011
Popis: Objectives To perform an adjusted indirect comparison of the efficacy of enzalutamide and apalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of progression to metastatic disease. Material and methods After carrying out a literature search, we performed an adjusted indirect comparison (Bucher et al.) of the relative efficacy of enzalutamide and apalutamide in patients with nmCRPC with a high risk of progression to metastatic disease. The outcomes included were metastasis-free survival (MFS) and PSA response rate (PSARR). Results There were no statistically significant differences between enzalutamide and apalutamide regarding the analysed outcomes. For the comparison enzalutamide + ADT vs. apalutamide + ADT: MFS a HR (95% C I) = 1.036 (0.781–1.373) was obtained. For PSARR, a RR (95% CI) = 0.81 (0.339–1.938) was obtained. Conclusions The adjusted indirect comparison performed in this study shows that there are no statistically significant differences in terms of efficacy regarding MFS and PSARR between enzalutamide + ADT and apalutamide + ADT in patients with nmCRPC with a high risk of progression to metastatic disease. However, in order to confirm these results, an independent trial with direct comparison between both drugs would be required.
Databáze: OpenAIRE
Externí odkaz: